Insulin receptor A and IGF-1R in AML - Letter.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. microRNA-628 inhibits the proliferation of acute myeloid leukemia cells by directly targeting IGF-1R.OncoTargets and therapy · 2019
   Article
2. Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014
   Article
3. Peptide structure stabilization by membrane anchoring and its general applicability to the development of potent cell-permeable inhibitors.Chembiochem : a European journal of chemical biology · 2011
   Article

Corrections and comments

• Comment on
  Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.2009

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as